Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- US PII Study for Telomelysin-Keytruda Combo Begins for Esophageal Cancer
May 14, 2019
- Nichi-Iko Aims to Resume Stable Supply of Cefazolin by Year-End: Exec
May 14, 2019
- Avastin Top Selling Drug in Japan in April: Encise Snapshot
May 14, 2019
- Japan Ethical Drug Sales Up 0.5% in March: Crecon
May 14, 2019
- Kyorin Grabs Japan Negotiation Rights to Marketing Collaboration for MSD’s Cough Treatment
May 14, 2019
- Daiichi Sankyo’s Hypertension Drug Minnebro Now Available
May 14, 2019
- Eisai’s FY2018 Net Profit Jumps 22.3% on Merck Deal, Global Brands
May 14, 2019
- Sumitomo Dainippon’s Sales Down 1.6% on Price Cuts, Generic Erosions
May 13, 2019
- Sunovion to Push Different Dasotraline Trial Data in FDA Negotiations: Sumitomo Dainippon Chief
May 13, 2019
- Mitsubishi Tanabe Foresees 82% Profit Dip in FY2019 as Gilenya Feud Weighs
May 13, 2019
- 70% of Drug Makers Shave New Grad Hiring, 100-Plus Recruits at Only 3 Firms: Jiho Survey
May 13, 2019
- Eisai Nabs Japan Distribution Rights to MTX SC Injection
May 13, 2019
- Alzheimer's Consortium Selects Elenbecestat, BAN2401 for Prevention Studies
May 13, 2019
- Entyvio’s SC Form Accepted by US FDA for Review: Takeda
May 13, 2019
- Sunovion’s Schizophrenia Agent Awarded US Breakthrough Therapy Designation
May 13, 2019
- Shionogi's FY2018 Sales Up 5.5% on HIV Royalties, Xofluza Notches 26.3 Billion Yen
May 10, 2019
- Ono Chief Touts 3-Pronged Recipe for Opdivo Comeback as I/O Pioneer
May 10, 2019
- Eisai to Invest 15 Billion Yen to Excavate Innovative Technology; 1st Pact Signed with App Developer
May 10, 2019
- Takeda to Divest Dry Eye Drug to Novartis for US$5.3 Billion
May 9, 2019
- Japan Generic Makers Cutting Back on New Grad Hiring in Near-Saturated Market: Jiho Survey
May 9, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…